By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Camurus 

Ideon Science Park
Solvegatan 41
Lund    SE-22370  Sweden
Phone: 46-46-2865730 Fax: 46-46-2865739


SEARCH JOBS


Industry
Biotechnology

Segment
Drug Delivery





Company News
Braeburn Pharma And Camurus Announce Submission Of NDA For Long-Acting Buprenorphine (CAM2038) For Opioid Use Disorder 7/20/2017 6:43:31 AM
Camurus And Braeburn Pharma Announce Topline Phase II Results For Long-Acting Buprenorphine In Opioid Dependent Patients With Chronic Pain 7/12/2017 8:35:42 AM
Rhythm And Camurus Announce Positive Initial Data For Extended-Release Delivery Of Setmelanotide For The Treatment Of Rare Genetic Disorders Of Obesity 6/27/2017 6:49:49 AM
Braeburn Pharma And Camurus Announce Presentations Of Pivotal Clinical Study Data Of Long-Acting Buprenorphine 6/15/2017 8:45:29 AM
Braeburn Pharma And Camurus Announce Positive Top-Line Results From Long-Term Phase III Safety Study Of CAM2038 5/2/2017 6:34:41 AM
Braeburn Pharma And Camurus Announce Positive Top-Line Phase 3 Results For Long-Acting Buprenorphine (CAM2038) For Treatment Of Opioid Addiction 11/14/2016 6:30:35 AM
Braeburn Pharma And Camurus Expand Collaboration And License Agreement To Include New Combination Product For Pain and Nausea 10/24/2016 12:32:34 PM
Braeburn Pharma And Camurus Expand Collaboration And License Agreement To Include New Combination Product For Pain And Nausea 10/24/2016 6:52:44 AM
Braeburn Pharma And Camurus Enroll First Patients In A Phase 3 Efficacy Trial Of CAM2038 For Treatment Of Chronic Low Back Pain 9/30/2016 6:45:22 AM
Camurus: Interim Report January-June 2016 7/14/2016 10:46:20 AM
1234
//-->